Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
US |
|
Unid Co Ltd
KRX:014830
|
KR |
Multiples-Based Value
The Multiples-Based Value of one
PIRS
stock under the Base Case scenario is
0.8285
USD.
Compared to the current market price of 12.0296 USD,
Pieris Pharmaceuticals Inc
is
Overvalued by 93%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
PIRS Competitors Multiples
Pieris Pharmaceuticals Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
100.1m USD | 74 | -6.3 | -4.5 | -4.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
376.8B USD | 6.3 | 91.5 | 15.1 | 21 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD | 111.3 | -1 738.3 | 16 147.7 | -1 823.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.1B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.2B USD | 5.8 | 19.9 | 12.4 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.6B USD | 9.4 | 28.5 | 21.4 | 22.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.7 | 18.1 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD | 3.1 | 34.8 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |